Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-31

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the anesthetic success of inferior alveolar nerve block (IANB), intraoperative pain intensity and need for supplemental anesthesia on administration of 1.8ml or 3.6ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine buccal infiltration (BI) in mandibular molars with symptomatic irreversible pulpitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis

NCT04822415

Symptomatic Irreversible Pulpitis

COMPLETED NA

Anesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine

NCT03725579

Symptomatic Irreversible Pulpitis

UNKNOWN PHASE2/PHASE3

Anesthetic Efficacy of 1.8 ml Versus 3.6 ml of 4% Articaine Buccal Infiltration

NCT06119139

Symptomatic Irreversible Pulpitis

NOT_YET_RECRUITING NA

Two Approaches in Enhancing the Efficacy of Inferior Alveolar Nerve Block During Treatment of Mandibular First Permanent Molars With Symptomatic Irreversible Pulpitis

NCT05427903

Pain, Procedural

UNKNOWN NA

Effect of Addition of Mannitol to Bupivacaine on IANB Success and Post-endodontic Pain

NCT03749408

Irreversible Pulpitis

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with moderate-to-severe preoperative pain related to mandibular molars with symptomatic irreversible pulpitis will be included. Patients receive 1.8 ml, 3.6 ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine BI. Anesthetic success of inferior alveolar nerve block, intraoperative pain intensity and need for supplemental anesthesia will be assessed during treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptomatic Irreversible Pulpitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.8 ml mepivacaine IANB

Group Type ACTIVE_COMPARATOR

1.8 ml mepivacaine hydrochloride

Intervention Type DRUG

1.8 ml mepivacaine IANB

3.6 ml mepivacaine IANB

Group Type EXPERIMENTAL

3.6 ml mepivacaine hydrochloride

Intervention Type DRUG

3.6 ml mepivacaine IANB

1.8 ml mepivacaine IANB plus 1.8 ml articaine BI

Group Type EXPERIMENTAL

1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI

Intervention Type DRUG

1.8 ml mepivacaine IANB plus 1.8 ml articaine BI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

1.8 ml mepivacaine hydrochloride

1.8 ml mepivacaine IANB

Intervention Type DRUG

3.6 ml mepivacaine hydrochloride

3.6 ml mepivacaine IANB

Intervention Type DRUG

1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI

1.8 ml mepivacaine IANB plus 1.8 ml articaine BI

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients in good health (ASA Class I, II).
2. Age between 18-60 years old.
3. Males or females.
4. Mandibular molar teeth diagnosed with symptomatic irreversible pulpitis.
5. Patients who can understand NRS scale and sign the informed consent.

Exclusion Criteria

1. Patients who had used any type of analgesic medication during the preceding 8 hours before the treatment.
2. Pregnant or nursing females.
3. Patients with a contraindication for the use of mepivacaine, articaine or any used drug or material.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No